nicht geprüft - aber als "Begründung" für den heutigen Börsenanstieg...
Was meinen die Experten hier (nicht zur Börse - sondern zum Text..)??
By Robert Langreth
(Bloomberg) -- An experimental vaccine from Moderna Inc.
showed promising early signs that it can create an immune-system
response in the body that could help fend off the new
coronavirus, according to sampling of data from a small, first
human trial of the inoculation.
The study was primarily designed to look at the safety of
the shot and showed no major warning signs in a small phase 1
trial, the company said in a statement Monday. The trial is
being run with the U.S. government, and Moderna plans to
continue advancing it to wider testing.
Researchers also looked at blood samples from the test
subjects and whether the vaccine helped them generate antibodies
that could fight off an infection. The researchers found that at
two lower dose levels used in the study, levels of antibodies
found after getting a second booster shot of the vaccine either
equaled or exceeded the levels of antibodies found in patients
who had recovered from the virus.
“This is a very good sign that we make an antibody that can
stop the virus from replicating,” Moderna Chief Executive
Officer Stephane Bancel said in an interview. The data “couldn’t
have been better,” he said.
Bancel said that safety profile appeared to be good, and
the reactions were typical of vaccines. They included injection
site pain and redness, as well as temporary fever or chills that
quickly go away on their own, he said.
Bancel said the company felt it needed to release the
interim data from the trial because of the high level of
interest in the vaccine.
A phase 2 trial is expected to begin shortly, and Moderna
said in its statement that a final-stage trial will begin in
July.
To contact the reporter on this story:
Robert Langreth in New York at
rlangreth@bloomberg.net
To contact the editor responsible for this story:
Drew Armstrong at
darmstrong17@bloomberg.net
gemeinsam zwiften |
youtube |
forum heute
